Helicobacter Pylori Resistance

NCT ID: NCT05019586

Last Updated: 2021-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

185 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-15

Study Completion Date

2020-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of the study was to characterize the morbidity, immunological, microbiolical and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP) infection, and the effect of triple therapy including the levofloxacin. Control groups were newly diagnosed, previously infected and never infected HP patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

See Nestegard O, et al. PLOS ONE \| https://doi.org/10.1371/journal.pone.0238944 September 23, 2020

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Helicobacter pylori resistance

Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days

levofloxacin, amoxicillin, clarithromycin

Intervention Type DRUG

Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days

Newly diagnosed Helicobacter pylori

Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days

levofloxacin, amoxicillin, clarithromycin

Intervention Type DRUG

Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days

Previously eradicated Helicobacter pylori infection

Patients with previously Helicobacter pylori infection included from 2010-2012.

No interventions assigned to this group

Never Helicobacter pylori infection

Patients with previously Helicobacter pylori infection included from 2010-2012.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

levofloxacin, amoxicillin, clarithromycin

Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients referred to a GI- unite with upper GI complains and performing an upper endoscopy -

Exclusion Criteria

Patients with severe chronic diseases and not willing to participate
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital of North Norway

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jon Florholmen

professor, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jon Florholmen

Role: PRINCIPAL_INVESTIGATOR

Department of Gastroenterology, Norwegian Artic University/Universiuty of Tromsø, Norway

References

Explore related publications, articles, or registry entries linked to this study.

Nestegard O, Moayeri B, Halvorsen FA, Tonnesen T, Sorbye SW, Paulssen E, Johnsen KM, Goll R, Florholmen JR, Melby KK. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS One. 2022 Apr 20;17(4):e0265322. doi: 10.1371/journal.pone.0265322. eCollection 2022.

Reference Type DERIVED
PMID: 35442962 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

University Hosp North Norway

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.